# L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

> clinical trial · VERIFIED · 2026-06-17

Status: RECRUITING · Sponsor: Moleculin Biotech, Inc. · Condition: Acute Myeloid Leukaemia (AML)

- Company: Moleculin Biotech, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06788756

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.